Pharmaceuticals
Search documents
How the Euro at $1.16 Changes Everything About These 3 Europe ETFs
Yahoo Finance· 2026-03-26 13:10
IEUR is BlackRock's entry in the core Europe category, and its cost structure is hard to beat. The expense ratio sits at 0.1%, and annual portfolio turnover is just 4%, keeping the fund tax-efficient and cheap to hold over time. Assets under management total $7.7 billion, making it one of the most liquid European equity ETFs available to US investors.Have You read The New Report Shaking Up Retirement Plans ? Americans are answering three questions and many are realizing they can retire earlier than expected ...
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting DCCR Safety Timeline: SueWallSt
Prnewswire· 2026-03-26 13:00
<!doctype html> <!-- For structured data --> <!-- For language declaration --> SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting DCCR Safety Timeline: SueWallSt <!-- Additional Authorable Meta tags --> Accessibility StatementSkip NavigationKey Dates and Disclosure Events Shareholders Need to KnowNEW YORK, March 26, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Soleno T ...
Achieve Life Sciences Flags FDA Observations While Pushing Launch To 2027 For Smoking Cessation Med
Benzinga· 2026-03-26 12:58
Achieve Life Sciences Inc. (NASDAQ:ACHV) shares are up during Thursday's premarket session. Year to date, the stock has fallen around 43%.Achieve Life Sciences Partners For US ManufacturingOn Tuesday, the company announced a partnership with U.S.-based Adare Pharma Solutions for the manufacturing of cytisinicline.Achieve Life Sciences selected Adare Pharma Solutions to manufacture its cytisinicline drug product to address nicotine dependence.The partnership is expected to reduce risks associated with intern ...
Medicus Pharma advances SkinJect, Teverelix programs, eyes catalyst-rich 2026
Proactiveinvestors NA· 2026-03-26 12:39
About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...
Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability
Globenewswire· 2026-03-26 12:30
Preclinical findings show cytisinicline's minimal 5-HT3 serotonin receptor binding offers insight into observed low nausea rates in smoking and vaping cessation trialsSEATTLE and VANCOUVER, British Columbia, March 26, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced the publication of a manuscript in Nicotine & Tobac ...
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Globenewswire· 2026-03-26 12:30
– Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe – Advances Proposed Expedited Regulatory Approval Pathways in Japan and Saudi Arabia and Secures Fast Track Designation in the U.S. for QRX003 for NS Subsequent to the End of Q4 – Reports Continued Clinical Progress for QRX003 in Netherton Syndrome Clinical Studies including Data Supporting Longer Term Durable Treatment Effect and Safety Profile – P ...
Kodiak Sciences shares surge after eye drug succeeds in late-stage study
Reuters· 2026-03-26 12:12
Kodiak Sciences shares surge after eye drug succeeds in late-stage study | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Companies Kodiak Sciences Inc Follow Kodiak said the results support an application for approval with the U.S. Food and Drug Administration, and that it plans to accelerate the submission. Reporting by Siddhi Mahatole in Bengaluru; Editing by Leroy Leo Our Standards: The Thomson Reuters Trust Principles., opens ...
PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
TMX Newsfile· 2026-03-26 12:00
Leveraging its PharmaPatch™ experience, the Company is introducing PatchPrint™ to support existing microneedle patch programs and expand into on-demand personalized patch solutions, including peptide patches, branded wellness patches, manufacturing systems and commercial partnerships.Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it submitted a provisional patent applica ...
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Prnewswire· 2026-03-26 12:00
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions Accessibility StatementSkip Navigation ATLANTA, March 26, 2026 /PRNewswire/ -- Alzamend Neuro, Inc.(Nasdaq: ALZN) ("Alzamend"), a clinical- stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("B ...
Income Investors Face a Hard Truth About Pfizer’s Payout Safety
Yahoo Finance· 2026-03-26 11:55
Quick Read Pfizer (PFE) paid $9.771B in dividends against free cash flow of $9.076B in FY2025, exceeding cash generation by $695M, while its GAAP payout ratio stands at 126.5% and total debt rose to $67.4B as liquid assets fell to $13.6B. The adjusted EPS payout ratio of 53.4% appears healthy, but non-cash charges mask underlying cash pressure. Pfizer’s dividend safety hinges on free cash flow recovery in 2026, as the current payout consumes more cash than the company generates, a practice that cannot ...
